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Structural and functional alterations of the peritoneal membrane are a
significant problem in long-term peritoneal dialysis patients. The present
study has established a 3-dimensional (3D) cell culture system to study the
human pcritoneal fibroblast (HPFB) and to examine its proliferative
responses to cytokines and growth factors as well as dialysis effluent
obtained from patients during peritoneal infection. PDGF-Au, basic FGF
and li.-l induced a time and dose dependent increase in 3D-HPFB
proliferation. At day 9 proliferation, as assessed by MTT uptake, was
increased by 2.4-, 2.3- and 1.5-fold above control by PDGF-AB (50 ng/ml)
bFGF (50 ng/ml) and IL-lp (10 ng/ml), respectively (N = 5, P = 0.04 for
all). These effects could be inhibited by co-incubation with anti-PDGF-AH
antibody, anti-bFGF or IL-Ira, respectively. Exposure of 3D-l-IPFB to
TGF-p, did not result in an increase in cell proliferation. Incubation of
3D-HPFB with peritoneal macrophage (PM0) or human peritoncal
mesothelial cell (HPMC) conditioned medium also resulted in a time and
dose dependent increase in proliferation. At day 9, proliferation was
maximally increased 1.65- and 1.92-fold by peritoneal macrophage- and
mesothelial cell-conditioned medium, respectively. Cell free PDE, ob-
tained from CAPD patients during episodes of peritonitis, induced
3D-HPFB proliferation above control values (2- to 6.5-fold increases, N =
5, P < 0.05 for all). This mitogenic potential of PDE was reduced
following dilution, and with time following peritonitis there was a gradual
decrease in the mitogenic effect of PDE. The proliferative potential of
PDE was significantly reduced following co-incubation with IL-Ira (45.7%
inhibition), anti-hFGF (34.9% inhibition) and anti PDGF-AR (27.4%
inhibition). These data indicate that infected PDE causes fibroblast
hyperplasia which might potentially contribute to pro-fibrotic processes
during CAPD.
Continuous ambulatory peritoneal dialysis (CAPD) is a major
therapy for the treatment of end-stage renal disease. In these
patients the peritoneal membrane functions as a dialyzing organ
and forms the permeability barrier across which ultrafiltration and
diffusion occur. Loss of ultrafiltration capacity is a major compli-
cation associated with long-term CAPD [1—9]. The ultrastructural
changes observed in peritoneal biopsy studies include mesothelial
desquamation and sub-mesothelial fibrosis resulting from fibro-
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blast hyperplasia and increased extracellular matrix deposition [2,
6].
Although the initiation and progression of fibrosis is poorly
understood, an ongoing acute or chronic inflammatory response,
with the infiltration of leukocytes, appears to he a prerequisite for
its initiation [101. Data from studies of pulmonary, hepatic, renal
and skin fibrosis indicate that the fibrotic process involves a series
of overlapping phases, which eventually lead to irreparable dam-
age to the interstitium of the tissue involved [4, 11—14]. The initial
activation stage appears to he followed by interstitial cell hyper-
plasia and subsequent matrix remodeling, increased collagen
deposition and eventually tissue fibrosis. Peritoneal fibrosis is also
characterized by the presence of a prominent mononuclear cell
infiltrate [I• Biopsies obtained at autopsy from patients previ-
ously maintained on CAPD revealed the presence of chronic
mononuclear cell infiltration suggesting that these cells may be the
source of the mediators (cytokines and growth factors) responsi-
ble for initiating and/or perpetuating the fibrotic response. Sup-
port for this concept comes from earlier studies which demon-
strated that mononuclear derived cytokines can alter fibroblast
proliferation [15—18], proteoglycan synthesis [191 and chemotaxis
[20, 21]. A recent study has confirmed that activated peritoneal
macrophages reside within the peritoneal membrane of CAPD
patients [22].
The potential of the mesothelial cells that line the pleural and
peritoneal cavities to contribute to inflammation has recently
been revealed [23—301. In contrast, the contribution of the pen-
toneal fibroblasts, which reside within the sub-mesothelial inter-
stitium surrounded by extracellular matrix, to intraperitoneal
inflammatory and pro-fibrotic processes remains to he fully elu-
cidated.
The majority of in vitro fibroblast studies to date have utilized
monolayer cell culture systems. These, however, poorly mimic
their in vivo state, where peritoneal fibroblasts are embedded
within the extracellular matrix. Culturing HPFB within a 3-dimen-
sional matrix might therefore more closely mimic their in t'ivo
state, since it is clear that the extracellular matrix acts not only as
the structural scaffold of tissues but also provides signals via
integnin receptors that control cellular functions [31], including
chemotaxis [21, 321, proliferation [33, 34], extracellular matrix
production as well as morphology.
In the present investigation we describe the establishment of a
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Fig. 1. A and B. Morphological appearance of HPFB in monolayer
culture (x400). C. Morphological appearance of HPFB in 3-dimensional
culture (X400).
3-dimensional human peritoneal fibroblast (HPFB) culture sys-
tem in which the cells are maintained within a matrix of type I
collagen. These experiments have examined the regulation of
HPFB proliferation by growth factors and cytokines present in the
peritoneal cavity during peritoneal inflammation and by perito-
neal dialysis effluent (PDE) obtained from patients during epi-
sodes of peritonitis.
Our observations demonstrate that bFGF, PDGF and IL-i
induce 3D-HPFB hyperplasia. Peritoneal dialysis effluent ob-
tained during episodes of peritonitis is a potent inducer of
3D-HPFB proliferation, a fact which appears to be due to its IL-i,
hFGF and PDGF content.
Methods
All chemicals, unless otherwise stated, were obtained from
Sigma Chemical Company (Poole, UK). All tissue culture plastics
were purchased from Falcon, Becton-Dickinson (Oxford, UK).
PDGF-AB, PDGF-1313 and PDGF-AA were expressed in E. coil
harvested and purified as previously described [35, 36]. IL-Ira was
kindly supplied by Dr. Peter Scholtz (Schering AG, Berlin,
Germany). Basic FGF and TGF-[31, polyclonal goat anti-human
PDGF-Afl and polyclonal rabbit anti-human bFGF were from
R&D Systems (Oxford, UK). IL-i f3 was purchased from Ad-
vanced Protein Products (APP, Brierly Hill, UK), Endotoxin
contamination of recombinant material was < 0.7 pg/pg protein
as assessed by the limulus anioeboeyte lysate assay (Kahi Vitrum,
Stockholm, Sweden). Lipopolysaceharide (E. coli 055 B5) was
purchased from Sigma.
Isolation and culture of human peritoneal fibroblasts
Human peritoneal fibroblasts were isolated from omental tissue
of consenting patients undergoing elective abdominal surgery
(during the entire study tissue samples were obtained from more
than 400 donors), using a modification of a method previously
described for peritoneal mesothelial cells [37]. Omental tissue,
previously processed to remove the mesothelial cells, was incu-
bated with a solution of trypsin/EDTA (0.25% wt/vol/0.02%
wt/vol; Life Technologies Ltd, Paisley, UK) at 37°C under contin-
uous rotation for two 40-minute periods. Fresh trypsin/EDTA was
used during the second incubation and cell pellets were washed
with Hams F12 (Life Technologies) containing 10% fetal calf
serum (FCS; Biological Industries, Cumbernauld, UK) at the end
of each digestion. The isolated cells were plated onto 25 cm2
tissue culture flasks and maintained in Hams F12 medium sup-
plemented with penicillin (100 U/mI), streptomycin (100 gJml,
L-glutamine (2 mM) insulin (5 .tgIml), transferrin (5 .Lg/ml) and
hydrocortisone (0.4 p.g/ml) (all purchased from Life Technolo-
gies). Cells were propagated in culture medium containing 10%
FCS in a 37°C, humidified, 5% CO2 atmosphere, with a complete
change to fresh medium every three to four days.
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Establishment of homogenous HPFB cultures
Mesothelial cells, which have a cobblestone appearance at
confluence, occasionally contaminated HPFB cultures. In such
instances a differential sub-culture was performed. This procedure
utilizes the differential rate of cell attachment/detachment of the
two cell types to the plastic, with the HPFB attaching more rapidly
than the mesothelial cells; hence the latter can be removed by
washing prior to their attachment.
Immunocytochemical characterization of HPFB
Using indirect immunocytochemical techniques the HPFB were
characterized by the presence or absence of cytokeratin, (epithe-
lial/mesothelial cell marker), Factor VIII (endothelial cell mark-
er), vimentin, desmin and myosin (myogenic markers) and a-
smooth muscle actin. Cells were grown to confluence on 8-well
glass chamber slides (Life Technologies Ltd.), washed in phos-
phate buffered saline (PBS) and fixed in acetone:methanol (1:1
vol/vol at 4°C) for five minutes. The cells were subsequently
washed in PBS containing 0.9% bovine serum albumin prior to
incubation in the primary antibodies at room temperature for 45
minutes. The antibodies were as follows: anti-human Factor
VIlI-related antigen (MoAb), rabbit anti-human vimentin, rabbit
anti-human myosin, rabbit anti-swine desmin (IgGI) (all from
Dako Ltd, High Wycombe, UK), rabbit anti-human cytokeratin
(peptide 18, IgGi) and MoAb anti-human smooth muscle actin
(Sigma). After a further wash the appropriate secondary fluores-
cein-conjugated antibodies were added for a further 45 minutes
(FITC conjugated anti-rabbit IgG or anti-mouse IgG, both from
Sigma). Finally the cells were washed, mounted and viewed under
a Leitz Orthoplan fluorescence microscope (Leica UK Ltd, Mil-
ton Keynes, UK).
Identification and characterization of HPFB
HPFB in monolayer cultures showed both a bipolar (Fig. 1A)
and multipolar (Fig. 1B) morphology and stained positively for
vimentin and myosin and occasionally a-smooth muscle actin by
immunohistochemistry. The expression of the latter varied be-
tween 15 to 20% of cells depending on the individual culture.
Cultures were always negative for cytokeratin, Factor VIII and
desmin excluding contamination of HPFB cultures with epithelial,
endothelial or mesothelial cells.
Establishment of 3-dimensional HPFB cultures
Rat tail Type I collagen was prepared and lyophilized according
to the method of Cawstcn and Barrett [38J. The purity of the
preparation was confirmed by SDS-polyacrylamide gel electro-
phoresis. HPFB were established in 3-dimensional culture using a
modification of the method of Madri, Pratt and Tucker [39]. All
initial procedures were carried out on ice to prevent collagen gel
formation. Initial experiments established both the collagen gel
concentration and the seeding cell density required to establish a
reproducible 3D-HPFB culture system.
Briefly, lyophilized collagen was solubilized by the addition of
100 m acetic acid followed by the addition of pyrogen free water
(Baxter Healthcare Ltd., Egham, Surrey, UK), bringing the
concentration of acetic acid to 16 m. To I ml of collagen
solution, lOx RPM! (110 .il) containing 27 1.d sodium bicarbonate
(7.5% vol/vol; Life Technologies) was added. The solution was
then neutralized with sodium hydroxide solution (1 M, Life
Technologies). Gel formation was facilitated by incubating this
solution at 37°C for 10 minutes.
In experiments, using 24 well plates, 300 d of collagen solution
(4 mg/mI) was added to each well, while in 96 well plates, 40 1.d is
added per well. This dense collagen "plug" acts as a barrier to
prevent fibroblast migration and attachment to tissue culture
plastic. Once this dense gel was formed the HPFB suspension
(3 x io in 125 jil in 24 well plates, 1 x iO in 35 jsl in 96 well
plates) was mixed with an equal volume of the 4 mg/mI collagen
solution on ice and plated on top of the collagen plug. In 24 well
plates 250 iii was plated and 70 pi was plated in 96 well plates.
These were allowed to gel and Hams F12 medium containing 10%
FCS was added to the cultures. This medium was replaced every
three days.
Once established in 3D culture, HPFB assumed an essentially
bipolar morphology and were multiorientated throughout the gel
(Fig. IC). In 3D culture HPFB could be maintained in culture for
extended time periods (> 30 days).
Establishment of growth arrested 3D-HPFB
Preliminary experiments revealed that HPFB in 3D culture
could be rendered quiescent by incubating them for 72 hours in
serum-free Hams F12 medium. Under these conditions the cells
remained in a non-proliferative but viable state (as assessed by the
lack of lactate dehydrogenase release and normal cellular ATP
levels) for periods up to 30 days (Beavis and Topley, unpublished
data).
Measurement of 3D-HPFB proliferation: Direct cell counting
After appropriate stimulation, medium was removed from
above the 3D cultures by gentle aspiration, the gel was washed
twice in Hams F12, removed from the well and placed into a
sterile 1.5 ml micro-centrifuge tube (Eppendorf Safelock, Merck
Ltd, Atherstone, UK) containing 1 ml of 0.4 mg/mi coilagenase
(Type VIII; Sigma Chemical). The gels were incubated at 37°C,
with rotation, until the collagen was completely digested and the
cells released. The cell pellet was then harvested by centrifugation
(150 x g), washed in Hams F12 containing 10% FCS to inhibit the
collagenase, and the cells counted using a modified Neubauer
counting chamber.
3H thymidine incorporation and DNA measurement
Following defined stimulation 3D-HPFB cultures were pulsed
with I Ci/ml 3H-thymidine (Amersham International PLC,
Cardiff, UK) for 24 hours, washed twice with Hams F12 and the
gels digested with collagenase as described above. Cell pellets
were resuspended in 500 jsl of PBS. One hundred microliter
aliquots of released cells were solubilized with 0.1 N NaOH,
neutralized with 1 M HCI and counted in a scintillation counter
(Canberra Packard Instruments, Pangbournc, UK) following mix-
ing with scintillant (Optiphase, Canberra Packard Instruments).
Total cellular DNA was also measured in these same samples
using the method of Kissane and Robins [40]. Briefly, HPFB
digested from the gels (100 tl) were extracted with 0.1 M
potassium acetate in ethanol (on ice) and twice with 100% ethanol
and subsequently air dried. Calf thymus DNA, (Sigma Chemical)
dissolved in 1 M ammonium hydroxide, was used as standard. To
the dried samples and standards 40 sl of a 30% (wt/vol) solution
of 3,5-diaminobenzoic acid (dihydrochioride) (DabA) was added
and incubated at 60°C for 30 minutes. Thereafter, 800 jil of 0.6 si
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perchioric acid was added to each tube, vortexed and centrifuged
at 13,000 X g for two minutes. Four hundred mieroliters of the
supernatant was then transferred to fluorimeter tubes and the
fluorescence measured on a Perkin-Elmer 150 fluorimeter (Ap-
plied Biosystems, Warrington, UK) using an excitation wave-
length of 406 nm and an emission wavelength of 520 nm.
MTT assay
This assay determines viable cell numbers and is based on the
mitoehondrial conversion of the tetrazolium salt, 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MIT), into an in-
soluble formazan product. Briefly, after stimulation, culture me-
dium was removed from 3D-HPFB and 100 sl of MiT (5 mg/mI)
was added to 96 well plates for four hours at 37°C. The form azan
product generated was solubilized by the addition of 100 d of
20% SDS, 50% dimethylformamide, 2% acetic acid, 0.06% hy-
drochloric acid and incubated at 37°C overnight. The absorbanee
at 600 nm was recorded in an ELISA plate reader (Dynateeh MR
5000/340; Dynateeh Laboratories, Billingshurst, UK). There was a
direct correlation between cell numbers assessed by direct cell
counting of solubilized gels and the MIT assay irrespective of
donor (r = 0.995, P < 0.001; Fig. 2).
Comparison of proliferation measurement techniques
MTT assay, 3H-thymidine incorporation and DNA measurement.
Initially HPFB proliferation in 3D culture was assessed by direct
cell counting. This technique, however, required large numbers of
cells and could only be performed successfully in gels established
in 24 well plates. In order to maximize the potential of the system,
alternative techniques were developed to assess HPFB prolifera-
tion in 3D culture.
In a series of five experiments 3H-thymidine incorporation,
cellular DNA content and measurement of proliferation using the
MIT assay were compared to data obtained from parallel cell
counting experiments. There was a positive correlation between
cell numbers assessed by direct cell counting and the MIT assay
(N 35, r = 0.636, P < 0.001) and 3H-thymidine incorpora-
tion/g cellular DNA content (N = 35, r = 0.436, P < 0.01).
Subsequent experiments utilised the MIT assay to assess 3D-
HPFB proliferation.
Induction of 3D-HPFB IL-6 synthesis by cytokines and growth
factors
3D-EIPFB are grown in 24 well plates and growth arrested for
72 hours, washed twice, and subsequently stimulated for 24 hours
with the eytokines or growth factors described. 3D-HPFB super-
natants were removed, centrifuged at 13,000 x g and stored at
—70°C until assayed. The cells were then washed in Hams F12,
and the collagen gels digested with bacterial eoiiagenase. The
resulting cell pellet was washed with PBS and solubilized with 0.1
M sodium hydroxide. Total cellular protein was assessed using the
modified Bradford method [41]. All data for IL-fl production are
expressed as pg4tg cell protein.
IL-6 synthesis measurement
Synthesized IL-6 was measured in the culture supernatants of
control and stimulated 3D-HPFB by a specific sandwich ELISA as
previously described [421.
I-IPMC conditioned medium
Human peritoneal mesothelial cells (HPMC) were grown to
confluence in 24 well plates and growth arrested in M199 con-
taining 0.1% FCS for 48 hours as previously described [25—27, 43].
Cells were then washed three times in rest medium and stimulated
with either IL-lp (100 pg/mI) or TNFa (1000 pg/mi), or control
medium. Following a 24 hour incubation the HPMC supernatants
were removed, centrifuged at 13,000 x g and stored at —70°C
until required.
Peritoneal macrophage conditioned medium
Peritoneal macrophages (PM0) were harvested on ice, from
infection-free peritoneal dialysis effluent of patients undergoing
CAPD as previously described [44—46]. Isolated cell populations
were plated onto 35 mm Petri dishes and incubated at 37°C in a
5% CO2 incubator for 90 minutes. After this period the non-
adherent cells were removed by washing twice with warm Hams
F12. Conditioned medium was collected from adherent PMØ
following 18 hours incubation with Hams F12 alone. The
PM0-CM was centrifuged (13000 X g), aliquoted and stored at
—70°C until required.
Infected spent dialysate
Spent dialysate (PDE) was collected as previously described
[47] from CAPD patients. In the first group (patients A, B, D, E
and F), PDE was collected on the day of presentation with
peritonitis (day 1) and subsequently from the overnight dwells
over the next five days. In these same patients, infection free PDE
was collected three months after the resolution of infection
(Al-Fl) only if they had remained infection free for that three
month period. PDE was also collected from a second group of
patients with no history of peritonitis. PDE was collected on ice,
centrifuged at 2000 x g to remove cellular material and subse-
quently filtered (0.2 jLM Filter, Sartorius Ltd, Epsom, UK). The
sterile cell free PDE was aliquoted and stored at —70°C until
required.
Blocking and depletion experiments
In a separate series of experiments the proliferative responses
of 3D-HPFB to cytokines, growth factors or PDE were examined
in the presence of increasing concentrations of IL-Ira, anti-
PDGF-Al, or anti-bFGF (either alone or in combinations). An-
tagonists or antibodies were added to the agonist (IL-ira, anti-
PDCJF or anti-bFGF) and incubated for 60 minutes at 37°C prior
to the commencement of the experiment. Cell proliferation was
assessed by MiT assay as described previously.
Statistical analysis
All data are presented from experiments performed in triplicate
with HPFB prepared from at least five separate omental donors.
Statistical analyses were performed using the Wilcoxon signed
rank test for paired non-parametric data. All data are presented
as means SCM.
Results
Establishment of 3D-HPFB proliferative capacily
Initial experiments demonstrated that following exposure to
FCS, 1-IPFB numbers, as determined by cell counting, increased
over a period of 12 days. Cell numbers increased from 2.69 0.49
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significant for all doses of bFGF above 1 ng/ml and was maximal
at 50 ng/ml (2.3-fold above control; N = 5, z = 2.02, P = 0.04). In
contrast, stimulation of 3D-HPFB with TGF-/31 did not induce a
mitogenic response irrespective of the dose tested (Fig. 3D).
The addition of lipopolysaccharide (LPS) to 3D-HPFB (at
doses up to 10 sg/ml) did not have any effect on 3D-HPFB
proliferation (Control O.D. 0.242 0.05 vs. 0.231 0.05 at 10
gJml).
Mesothelial cell conditioned medium
(X 10) at the start of the experiment to 3.98 1.32 (x 10; N =
5, z = 1.96, P = 0.04) after three days. By day 9 HPFB numbers
had further increased to 6.3 1.39 (X iOn; N = 5, z = 1.96, P =
0.04), a 2.3-fold increase above control.
Growth arrest of 3D-HPFB cultures
To examine the proliferative responses of HPFB to growth
factors and cytokines in the absence of the confounding influence
of serum-derived growth factors, HPFB were established in 3D
cultures in a subeonfluent state and subsequently growth arrested
under serum free conditions. After 72 hours, of serum free
culture, cell numbers were not significantly different from con-
trols, (3.36 0.34 vs. 3.18 0.49 (x104;N = 5 experiments) and
remained constant for extended periods (at day 9, 3.07 0.31;
x 10). There was no evidence of cell toxicity as assessed by LDH
release (data not shown). As a result of these experiments, a
growth arrest period of 72 hours was judged to be sufficient to
render cells quiescent.
It was then necessary to establish whether 3D-HPFB were
capable of resuming their proliferative capacity following this 72
hours growth arrest period. After growth arrest the addition of
10% FCS resulted in a time dependent increase in 3D-HPFB
numbers. After nine days 3D-HPFB numbers had increased
threefold (6.639 2.12; x104) at day 9 versus 2.095 0.64 (X
10) in control (N = 5, z = 1.96, P = 0.04). These levels were
comparable to 3D-HPFB maintained in the continuous presence
of 10% FCS after seeding.
Mitogenic effect of cytokines and growth frictors on 3D-HPFB
The effects of PDGF-AB, IL-1, bFGF and TGF-131 on 3D-
HPFB proliferation were studied using the MIT assay. All three
isoforms of PDGF induced a time and dose dependent increase in
3D-HPFB proliferation, after nine days PDGF-AB, the most
potent isoform, increased 3D-HPFB numbers by 2.4-fold above
control (N = 5, z = 1.96, P = 0.04; Fig. 3A). IL-1f3 induced a
smaller but significant increase in proliferation (Fig. 3B). The
maximum response was achieved at the highest dose tested (10
ng/ml) where a 1.5-fold increase above control was observed (N =
5, z = 2.02, P = 0.04).
Stimulation of 3D-HPFB with bFGF also induced a dose
dependent increase in 3D-HPFB proliferation (Fig. 3C). This was
Peritoneal macrophage conditioned medium
Conditioned medium from PMØ induced 3D-HPFB prolifera-
tion, this effect was maximal with undiluted PM0-CM, and was
reduced to control levels following dilution. At day 9 3D-HPFB
proliferation (expressed as 0D600) was increased from 0.17 0.05
in control 3D-HPFB to 0.334 0.054 following exposure to
PM0-CM (a mean 1.96-fold induction; N = 5, z = 2.02, P = 0.04;
Fig. 4B).
Peritoneal dialysis effluent
Peritoneal dialysis effluent (PDE) samples obtained during
acute infection induced an increase in 3D-HPFB proliferation as
assessed by an increase in MiT absorbance. Initial experiments
compared the mitogenic potential of pooled infected PDE (ob-
tained from 5 patients on day 1 of infection), pooled non-infected
PDE, (obtained from 5 patients who had no history of peritonitis)
and 10% FCS. All induced a significant cell proliferation (as
assessed by MIT assay) above control with mean increases of 3.5-,
1.6- and 1.7-fold being induced by infected PDE, infection free
PDE and 10% FCS, respectively (N = 5 experiments, z = 2.023,
P = 0.04 vs. control for all; Fig. 5A). Cell counting experiments
confirmed that 3D-HPFB numbers increased during these exper-
iments. Infected PDE, pooled from all patients, induced an
increase in 3D-HPFB number from 3.45 1.6 (x 10) in control
to 7.79 1.8 (X 10) after nine days of incubation (a mean
1.9-fold induction; N = 5, z = 2.02, P = 0.04).
The level of stimulation induced by individual infected PDE
samples was greater than that seen with any individual growth
factor or cytokine. 3D-HPFB proliferation increased by between
2-fold and 6.5-fold above control, and was significant with all
infected PDE tested (N = 5 experiments, P < 0.05 for all). The
mitogenic potential of infected PDE was maximal on the day of
presentation; PDE obtained on subsequent days (from all pa-
tients) had significantly less mitogenic activity compared to day 1
and diminished with time after onset of infection.
In order to simulate the temporal changes occurring in the
inflammatory milieu during peritonitis, growth arrested 3D-HPFB
were successively exposed (for 24 hr in each case) to PDE
obtained on days 1, 2, 3, 4 and 5 of infection. At the end of the
experiment (day 6), cell proliferation was assessed by MIT assay.
Peritonitis effluents (days 1 to 5 sequentially added to HPFB)
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Fig. 3. Effect of (A) PDGF-AB (1 to 50 ng/ml), (B) IL-1[3 (0.001 to lOng/mI), (C) hFGF (Ito 50 ng/ml), and (D) TGF-p1 (1 to 50 ng/ml) on 3D-HPFB
proliferation at day 9, as assessed by MTT assay. Data are presented as means SEM from 5 experiments performed with 3D-HPFB from different donors.
*A statistically significant difference (P < 0.05) compared to growth arrested 3D-HPFB (Day 9).
from all patients (patients A, B, D, E and F) induced significant
proliferative responses (between 2.2- and 4-fold increases) com-
pared to control (N = 5, z = 2.02, P = 0.04 for all; Fig. 5B).
Parallel 3D-HPFB cultures were exposed for the same time
periods to PDE obtained from the same patients three months
after resolution of infection (Al, Bl, Dl, El and Fl). These
effluents still contained significant mitogenic potential for 3D-
HPFB. These increases (1.77- to 2.38-fold above control) were
significantly less than those increases seen in response to the PDE
obtained during peritonitis (N = 5, z = 2.023, P = 0.04 for all).
Blocking experimenis
In order to define those factors present in infected PDE which
might be responsible for inducing 3D-HPFB proliferation, block-
ing experiments were performed using increasing concentrations
of IL-Ira, anti-PDGF-A13 antibody or anti-hFGF antibody. Con-
trol experiments demonstrated that the proliferative responses
induced by IL-IS, PDGF-Au and bFGF alone could be dose
dependently inhibited by IL-ira, anti-PDGF-AII or anti-bFGF,
respectively (data not shown). Incubation of 3D-HPFB with the
blocking agents alone did not modulate cell proliferation.
Mitogenic potential in PDE
Pre-incubation of pooled infected PDE with increasing concen-
trations of IL-lra (0.1 to 10 JLg/ml), anti-PDGF-AD (2.5 to 10
jtg/ml) or anti-bFGF (12.5 to 50 g/ml) all significantly reduced
the proliferation in response to PDE (Fig. 6). Maximal inhibition
was achieved with the highest dose of IL-lra, which reduced
infected PDE induced 3D-HPFB proliferation by a mean of
45.7% (N = 5, z = 2.203, P = 0.027). Pretreatment with
anti-bFGF or anti-PDGF also significantly reduced the PDE
induced proliferation by 34.9% and 27.4%, respectively (N = 5,
z = 2.023, P = 0.04 for both). Combinations of all three blocking
agents (at the highest doses tested) resulted in the largest degree
of inhibition, with a mean (± so) 75.84 9.8% inhibition of
pooled infected PDE induced 3D-HPFB proliferation (N = 5,z =
2.203, P = 0.04 vs. pooled infected PDE). I-Teat treatment (95°C
for 1 hr) also reduced the mitogenic capacity of pooled infected
PDE, and in two separate experiments (with different HPFB
donors) the mitgenic capacity of infected PDE was reduced by
46.7 and 65.03%.
In additional experiments 3D-HPFB were stimulated with
either IL-1f3 in the presence of anti-PDGF-AB or hFGF in the
presence of IL-ira. In neither case was 3D-HPFB proliferation
reduced by a significant amount.
Induciion of 3D-1-IPFB IL-6 synthesis
Stimulation of growth arrested 3D-HPFB with IL-i 13 or TNFcs
resulted in a dose dependent generation of IL-6 (Fig. 7). After 24
hours a significant release (expressed as pg/jig cell protein) above
control levels (0.521 0.08) was achieved with doses of IL-113
above 1 pg/mI and TNFa above 100 pg/mI (N = 6, z = 2.023,P <
- cz
0
5o
Fig. 4. ,4.. Effect of human peritoneal mesothelial
cell HPMC) conditioned medium (HPMC-
Control, HPMC-JL-1f3, HPMC-TNFa) on the
proliferation at day 9 of 3D-HPFB as assessed by
MTT assay. Data are presented as (mean
SEM) from 5 experiments with cells from
different donors. *A statistically significant
difference (P < 0.05) compared to growth
arrested 3D-HPFB (Day 9). B. Effect of PM0-
CM conditioned medium on the proliferation at
day 9, of 3D-HPFB as assessed by MIT assay.
Data are presented as (mean SEM) from 5
experiments with cells from different donors.
*A statistically significant difference (P < 0.05)
compared to growth arrested 3D-HPFB (Day
9).
0.028 for both). Maximal IL-6 levels were stimulated by IL-i j3
(1000 pg/mI) and TNFa (1000 pg/ml) (6.47 1.41 and 1.24
0.315, respectively; N = 6, z = 2.203, P < 0.028 for both). The
levels of IL-6 secreted by 3D-HPFB in response to stimulation
with combinations of IL-1f3 and TNFs were significantly different
from the IL-6 levels generated by the two cytokines alone, at the
highest combined doses (IL-113, 100 pg/mI and TNFn, 1000
pg/ml). Under these conditions the amount of IL-6 released
(6.86 0.911) was 1.5-fold above the additive values (N = 6, z =
2.203, P < 0.027).
Discussion
Ultrafiltration failure is a major factor limiting the long-term
use of peritoneal dialysis [1, 48]. It is assumed that progressive
fibrotic events within the interstitium contribute to modulation of
peritoneal membrane structure and function [4, 81. Little is
known, however, about how these events are initiated and
progress, and to what extent the resident cells of the peritoneal
membrane (resident and infiltrating macrophages, mesothelial
cells and interstitial fibroblasts) contribute to this process. It is
clear, however, that infection/inflammation (both its frequency
and severity) plays a significant role [48].
The process of inflammation within the peritoneal cavity of
CAPD patients has been characterized by both & vivo measure-
ments of effluent cytokine levels and in vitro cell culture of
peritoneal membrane cell populations [23—27, 37, 49—54]. These
observations suggest that control of peritoneal inflammation
involves the products of the macrophage and the mesothelium
[28J.
Within the peritoneal membrane there exists a third population
of cells, the peritoneal fibroblasts. This cell type has only recently
been isolated and its contribution to the normal function of the
peritoneal membrane as well as its responses to inflammatory
processes remains to he determined. During peritoneal inflamma-
tion the levels of cytokines, especially IL-6, are elevated [53]. It
has been previously suggested that the mesothelium is the major
source of IL-6 present during peritoneal inflammation [25, 53, 55].
The synergistic induction of lL-6 synthesis in conditions that
mimic peritoneal inflammation suggest that HPFB potentially
contribute to this secretion. The role of IL-6 in the peritoneal
cavity remains to he fully defined, however, it has been suggested
that it plays both an anti-inflammatory role as well as being
potentially involved in peritoneal transport [56].
Most in vitro fibroblast studies have utilized monolayer cell
A
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Fig. 5. A. Effect of pooled infected PDE (obtained from 5 patients at
presentation of infection), pooled non infected PDE (obtained from 5 patients
without a histoiy of peritonitis) and 10% FCS on 3D-HPFB prolifrration at
day 6, as assessed by MTT assay. Data are presented as (mean suM) from
S experiments with cells from different donors. *A statistically significant
difference (P < 0.05) compared to growth arrested 3D-HPFB (Day 6). II.
Effect of overnight infected PDE obtained from 5 different patients (A, B,
D, E and F) (PDE was obtained on days 1, 2, 3, 4 and 5 of infection) and
infection free PDE (Al, Bi, Dl, El and Fl) obtained three months later
from the same patients on 3D-HPFB proliferation. PDE was added to
3D-HPFB on 5 successive days (day I PDE on day I, day 2 PDE on day
2, etc.) and 3D-HPFB proliferation assessed at day 6 by M'IT assay. Data
are presented as (mean SuM) from 5 experiments with cells from
different donors. *A statistically significant difference (P < 0.05) com-
pared to growth arrested 3D-HPFB (Day 6).
culture systems to investigate fibroblast function. As the extracel-
lular matrix provides important signals that modulate cellular
behavior [31] and peritoneal fibroblasts reside within the sub-
mesothelial interstitiuni embedded within the extracellular matrix,
we reasoned that culturing HPFB within a 3-dimensional matrix
might more closely mimic their in vivo state. This study describes,
for the first time, the routine isolation and culture of 3D-HPFB
and their establishment and propagation in a 3-dimensional
collagen matrix.
In monolayer culture, 3D-HPFB exhibited either the classical
bipolar spindle morphology, or more frequently, a flattened,
multipolar/stellate appearance. Within the 3D collagen matrix,
cell morphology was altered with cells displaying an accentuated
spindle morphology. Immunocytochemical characterization of
P=0.04
_ nfl
PDE IL-iRA PDE anti-bFGF PDE anti-PDGF
Fig. 6. Effect of IL-Ira (10 p.g/ml), anti-PDGF-AB (10 pg/mI) or anti-bFGF
(50 jig/mI) on 3D-HPFB proliferation at day 6, induced by pooled infected
PDE. Data are presented as (mean SEM) from 5 experiments with cells
from different donors. *A statistically significant difference (P < 0,05)
compared to growth arrested 3D-HPFB (Day 6).
these cells, in monolayer culture, showed them to be negative for
cytokeratin, desmin and Factor VIII, excluding contamination
with endothelial and mesothelial cells, and positive for vimentin,
myosin and occasionally, in proliferating cells, a-smooth muscle
actin. This expression of muscle differentiation features in fibro-
blasts has previously been described in both physiological and
pathological settings [57]. Fibroblasts expressing such features
have been termed myofibroblasts, and are associated with pulmo-
nary and renal fibrotic diseases [57]. It has previously been
observed that the cytoskeletal profile of fibroblasts maintained in
a 3D collagen matrix differs from that seen in monolayer culture
[12], confirming that the interaction of cells with the collagen
matrix modulates their behavior.
The extracellular matrix is known to exert influence over many
cellular functions, including proliferation and secretion. Several
investigators have observed reduced proliferative potential of
fibroblasts in 3D collagen gels as compared to monolayer cultures
[58—60]. The turnover of extracellular matrix and matrix mRNA
expression are also modified with various investigators observing
modulation of collagen synthesis, mRNA expression, collagenase
activity and proteoglycan composition [61—64].
Interstitial cell hyperplasia is thought to be an important
initiating step in the fibrotic process [65, 661. In the present study,
we chose to focus on the proliferative responses of 3D-HPFB to
cytokines and growth factors previously identified as being impor-
tant in other fibrotic conditions. Initial experiments demonstrated
that, in our extended culture system, IL-iD, all isoforms of PDGF,
and hFGF were mitogenic for 3D-HPFB. All induced both a time
and dose dependent increase in 3D-HPFB proliferation as as-
sessed by a variety of standard techniques. Under the same
conditions TGF-f31 was not mitogenic for 3D-HPFB.
Interleukin-1 has been shown to increase fibroblast prolifera-
tion in many systems [10, 67—69]. This mitogenic action of IL-i on
fibroblasts is postulated to he indirect and mediated by induction
of PDGF-A chain synthesis [69]. In our studies, however, IL-I
induced 3D-HPFB proliferation could not be inhibited by anti-
PDGF antibody. There is considerable evidence that PDGF and
hFGF participate in the initiation of fibrotic diseases particularly
in the kidney [70], and both are potent mitogens for many cell
types [71, 721. In our system both PDGF and bFGF were potent
mitogens for 3D-HPFB over a wide dose range.
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Fig. 7. Induction of IL-6 synthesis by 3-D HPFB
in response to IL-I 13 or TNF combinations of
the two. Data are presented as the mean (±
SEM) of 6 experiments performed with different
cell preparations. Symbols are: (t) IL-113, ()
TNFcs, and (LI) IL-I /3 + TNFa.
The most pronounced mitogenic effect upon 3D-HPFB, how-
ever, occurred following incubation of 3D-HPFB with infected
spent dialysate. Dialysate collected on the first day of the infection
induced the greatest mitogenic response, with fluids taken from
subsequent days showing a significantly diminished effect. Inter-
estingly, PDE obtained from patients three months after the
resolution of infection or in patients without a history of perito-
nitis still contained significant mitogenic potential. These data
concur with those of Selgas et al, who observed a highly variable
effect of uninfected PDE on mouse fibroblast proliferation [73].
These authors, however, did not determine the nature of this
mitogenic activity.
Inhibition experiments revealed that the mitogenic potential
present in infected PDE was heat labile and related to its IL-I and
also to its bFGF and PDGF content. In this respect, it has recently
been demonstrated that infected PDE contains significant quan-
tities of IL-i [50, 74] that are reduced as infection resolves. There
are no reports on PDGF and bFGF levels in PDE; however, our
preliminary Western blot data suggest that both proteins are
detectable in both infected and noninfected PDE (Beavis and
Topley, unpublished data).
As mentioned previously, PMØ and the mesothelium are
believed to contribute to the control of peritoneal inflammation.
We investigated whether these cells might be the source of the
mitogenic molecules present in PDE. Conditioned medium ob-
tained from both PMØ and HPMC induced 3D-HPFB prolifera-
tion, confirming that both cell types were capable of contributing
to the mitogenic activity present in PDE.
The implications of these findings remain to he determined.
Recent data, however, suggest that ultrafiltration failure in long-
term CAPD is associated with the frequency and severity of
peritonitis episodes [48]. These data suggest that during the
process of infection, factors are released that contribute to the
initiation of membrane dysfunction. Clearly, however, the perito-
neal membrane is capable of recovering, at least in the short term,
from a single infectious episode, but frequent infection is obvi-
ously detrimental to long-term membrane function. Loss of
ultrafiltration, however, also occurs in patients without a history of
peritonitis [1, 4, 48], which suggests that other mechanisms, such
as continuous exposure to unphysiological dialysis fluids or ongo-
ing sub-clinical inflammation, might contribute to this process.
The data from the present study suggest that significant mito-
genic potential exists within PDE and that this is significantly
increased during peritoneal infection. Within the peritoneum,
therefore, there exist mechanisms by which inflammatory activa-
tion is controlled and the outcome in terms of peritoneal fibrosis
depends on the balance of normal healing process versus those
processes which result in the initiation and propagation of the
fibrotic process. Our data suggest that the peritoneal fibroblast
may be centrally involved in both the normal and pathological
processes occurring within the CAPD peritoneum.
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Appendix
Abbreviations are: IIPFB, human peritoneal fibroblasts; 3D-HPFB,
HPFB in 3-dimensional cell culture; hFGF, basic fibroblast growth factor;
CAPD, continuous ambulatory peritoneal dialysis; FCS, fetal calf serum;
HPMC, human peritoneal mesothelial cell; HPMC-CM, human perito-
neal mesothelial cell conditioned medium; IL-if3, interleukin-1/3; IL-Ira,
intcrleukin-i receptor antagonist; LPS, lipopolysaccharidc; Mfl', 3[4,5-
diniethylthiazol-2-yll-2, 5-diphenyltetrazolium bromide; PDE, peritoneal
dialysis effluent; PDGF, platelet-derived growth factor; PMØ, peritoneal
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macrophage; PM0-CM, peritoneal macrophage conditioned medium;
TGF-1, transforming growth factor-1.
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